Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA1 | P00915 | 12/20 | 0.52 |
| ▸ | CA9 | Q16790 | 10/20 | 0.52 |
| ▸ | CA5A | P35218 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA6 | P23280 | 4/20 | 0.52 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1281418 | 0.88 | CA2 (0.46) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL2069124 | 0.86 | CA2 (0.52) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL28345243 | 0.86 | CA2 (0.52) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL7194865 | 0.84 | CA2 (0.50) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL19857593 | 0.83 | HSD11B1 (0.49) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL29418255 | 0.80 | MEN1 (0.56) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL302570 | 0.80 | MEN1 (0.56) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL10407302 | 0.79 | CA2 (0.45) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL10587163 | 0.79 | CA2 (0.45) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL14524138 | 0.79 | CA2 (0.45) | CA2CA1CA9CA5ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150267232-A1 | IN VIVO AND IN VITRO CARBENE INSERTION AND NITRENE TRANSFER REACTIONS CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150267232-A1 | IN VIVO AND IN VITRO CARBENE INSERTION AND NITRENE TRANSFER REACTIONS CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150267232-A1 | IN VIVO AND IN VITRO CARBENE INSERTION AND NITRENE TRANSFER REACTIONS CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150267232-A1 | IN VIVO AND IN VITRO CARBENE INSERTION AND NITRENE TRANSFER REACTIONS CATALYZED BY HEME ENZYMES | HMBS, HMOX1, HMOX2 | CA2 1579/4885CA1 2759/4885CA9 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.